Exhibit 461

Report 57: 542 Neurological Adverse Events, 95% Serious, in First 90 Days of Pfizer mRNA Vaccine Rollout. 16 Deaths. Females Suffered AEs More Than Twice as often as Males

https://dailyclout.io/report-57-542-neurological-adverse-events-95-serious-in-first-90-days-of-pfizer-mrna-vaccine-rollout-16-deaths-females-suffered-aes-more-than-twice-as-often-as-males/

Report 57: 542 Neurological Adverse Events, 95% Serious, in First 90 Days of Pfizer mRNA Vaccine Rollout. 16 Deaths. Females Suffered AEs More Than Twice As Often As Males.

February 20, 2023 • by Joseph Gehrett, MD; Barbara Gehrett, MD; Chris Flowers, MD; and Loree Britt

The War Room/DailyClout Pfizer Documents Analysis Project Post-Marketing Group (Team 1) – Barbara Gehrett, MD; Joseph Gehrett, MD; Chris Flowers, MD; and Loree Britt – produced an alarming review of the neurological System Organ Class (SOC) adverse events found in Pfizer document *5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-FEB-2021* (https://www.phmpt.org/wp-content/uploads/2022/04/reissue_5.3.6-postmarketing-experience.pdf) (a.k.a., "*5.3.6*"). This SOC includes altered function of the brain, spinal cord, or peripheral nerves.

It is important to note that the adverse events (AEs) in the *5.3.6* document were reported to Pfizer for only a 90-day period starting on December 1, 2020, the date of the United Kingdom's public rollout of Pfizer's COVID-19 experimental mRNA "vaccine" product.

Key points in this report include:

- 542 neurological events, **95% of which were serious**, occurred in 501 patients.
- **16 patients died**.
- **50% of events occurred within the first 24 hours** after injection, equating to over 270 events in a single day.
- **69% of the neurological events affected females**, and 31% occurred in males.
- **376 seizures** were reported, twelve of which were **"status epilepticus** (https://www.ncbi.nlm.nih.gov/books/NBK430686/)," a rare condition of prolonged seizure or series of seizures that is **life-threatening**.
- **38 cases of multiple sclerosis (https://www.nationalmssociety.org/What-is-MS)**.
- **11 cases of transverse myelitis (https://www.hopkinsmedicine.org/health/conditions-and-diseases/transverse-myelitis)** (*a destructive inflammation of the spinal cord*).
- **10 cases of optic neuritis (https://www.aao.org/eye-health/diseases/what-is-optic-neuritis)** (*inflammation of the optic nerve threatening blindness*).
- **24 cases of Guillain-Barré syndrome (https://www.ninds.nih.gov/health-information/disorders/guillain-barre-syndrome)**, ascending paralysis from nerve inflammation.
- **Three cases of meningitis (https://my.clevelandclinic.org/health/articles/14600-meningitis)** (*infection and inflammation of the fluid and membranes surrounding the brain and spinal cord*).
- **Seven cases of encephalopathy (https://www.ninds.nih.gov/health-information/disorders/encephalopathy)** (*any disease of the brain that alters brain function or structure; hallmark is altered mental state*).
- Only adverse events that occurred *two or more times* are specifically reported in the diagnoses list. There were twenty events that happened once and, thus, were not included.

DAILYCLOUT

War Room/DailyClout Pfizer Document Analysis

Post-Marketing Team Micro-Report 7:

Neurologic SOC Review of 5.3.6

SOURCE

https://www.phmpt.org/wp-content/uploads/2022/04/reissue_5.3.6-postmarketing-experience.pdf

5.3.6 AE REPORTING PERIOD:

"Since the first temporary authorization for emergency supply under Regulation 174 in the UK (01 December 2020) and through 28 February 2021."

5.3.6 AE CASES/EVENTS:

TOTAL AE CASES: 42,086

TOTAL AE EVENTS: 158,893

ABBREVIATIONS:

5.3.6 : Pfizer source document

SOC : System Organ Class

AE : Adverse Event

AESI : Adverse Event of Special Interest

EUA : Emergency Use Authorization by FDA

PM : Post-Marketing

BNT162b2 : Pfizer's mRNA COVID-19 vaccine

AGE GROUPS defined in 5.3.6 (p. 25 footnote) :

Adult	18 - 64
Elderly	≥ 65
Child	2 - 11
Adolescent	12 - < 18
Infant	1 – 23 months

AUTHORS:

Dr Joseph Gehrett MD
Dr Barbara Gehrett MD
Dr Chris Flowers MD
Loree Britt

Post Marketing Team

19Feb23

Of the 542 neurological adverse events **95%** were defined as serious. **16** were fatal.

Neurological AESIs (including demyelination) *Search criteria: Convulsions (SMQ) (Broad and Narrow) OR Demyelination (SMQ) (Broad and Narrow) OR PTs Ataxia; Cataplexy; Encephalopathy; Fibromyalgia; Intracranial pressure increased; Meningitis; Meningitis aseptic; Narcolepsy*	• Number of cases: 501 (1.2% of the total PM dataset), of which 365 medically confirmed and 136 non-medically confirmed. • Country of incidence (≥9 cases): UK (157), US (68), Germany (49), Mexico (35), Italy (31), France (25), Spain (18), Poland (17), Netherlands and Israel (15 each), Sweden (9). The remaining 71 cases were from 22 different countries. • Subjects' gender (n=478): female (328), male (150). • Subjects' age group (n=478): Adult (329), Elderly (149); • Number of relevant events: 542, of which 515 serious, 27 non-serious. • Most frequently reported relevant PTs (>2 occurrences) included: Seizure (204), Epilepsy (83), Generalised tonic-clonic seizure (33), Guillain-Barre syndrome (24), Fibromyalgia and Trigeminal neuralgia (17 each), Febrile convulsion, (15), Status epilepticus (12), Aura and Myelitis transverse (11 each), Multiple sclerosis relapse and Optic neuritis (10 each), Petit mal epilepsy and Tonic convulsion (9 each), Ataxia (8), Encephalopathy and Tonic clonic movements (7 each), Foaming at mouth (5), Multiple sclerosis, Narcolepsy and Partial seizures (4 each), Bad sensation, Demyelination, Meningitis, Postictal state, Seizure like phenomena and Tongue biting (3 each); • Relevant event onset latency (n = 423): Range from <24 hours to 48 days, median 1 day; • Relevant events outcome: fatal (16), resolved/resolving (265), resolved with sequelae (13), not resolved (89) and unknown (161); Conclusion: This cumulative case review does not raise new safety issues. Surveillance will continue

https://www.phmpt.org/wp-content/uploads/2022/04/reissue_5.3.6-postmarketing-experience.pdf

- **Adverse Events were reported to Pfizer during a 90-day period, following the December 1, 2020, public rollout of its COVID-19 experimental "vaccine" product.**
- **In the Pfizer 5.3.6 document, these AEs were categorized by System Organ Classes (SOC) – in other words, by systems in the body.**
- **In the neurologic SOC, of those patients whose sex was reported, 69% were female and 31% were male.**
- **Of the 478 subjects with age reported, 329 were adult and 149 were elderly.**

Within each SOC, the adverse events are further classified as either "serious" or "non-serious." **Given the extremely high rate of "serious" neurological adverse events**, an understanding of the FDA's definition of this term is important. Below are excerpts from the official FDA website. Provided with this context, the full impact of the information presented in this report can be realized.

What is a Serious Adverse Event?

An adverse event is any undesirable experience associated with the use of a medical product in a patient. The event is serious and should be reported to FDA when the patient outcome is:

Death
Life-threatening
Hospitalization (initial or prolonged)
Disability or Permanent Damage
Congenital Anomaly/Birth Defect
Required Intervention to Prevent Permanent Impairment or Damage (Devices)
Other Serious (Important Medical Events)

https://www.fda.gov/safety/reporting-serious-problems-fda/what-serious-adverse-event

This category includes conditions of altered function of the brain, spinal cord, or peripheral nerves (nerves that connect to the spinal cord and extend to the rest of the body). Also included are conditions resulting from direct damage to nerve tissue. Pfizer chose to report fibromyalgia in this category. However, those conditions categorized by Pfizer under the general term peripheral neuropathy (abnormal nerve function) are reported separately in the SOC of "Immune-related/Autoimmune" adverse events. "Polyneuropathy" (multiple nerve dysfunction) is categorized under the SOC "Musculoskeletal" adverse events. The distribution of these diagnoses into various other SOCs is medically debatable. Bell's palsy with facial nerve damage is summarized in its own report.

https://dailyclout.io/wp-content/uploads/p1-Post-Marketing-Team-Neurologic-MicroReport.pdf (https://dailyclout.io/wp-content/uploads/p1-Post-Marketing-Team-Neurologic-MicroReport.pdf)

DAILYCLOUT

SOURCE:

https://www.phmpt.org/wp-content/uploads/2022/04/reissue_5.3.6-postmarketing-experience.pdf

OUTCOMES REPORTED:

Recovered/recovering	265
Recovered with sequelae	13
Not recovered	89
Unknown	161

SEQUELAE: an abnormal condition resulting from a previous disease, injury, or other trauma

To recap, **95%** of the adverse events were considered **serious**. **16 resulted in death**. Our review found the largest number of diagnoses were **seizures including generalized, petit mal and febrile.** There are **376** (69%) events of these types though notably **12** (3%) were **status epilepticus** (sustained seizures). This particular diagnosis deserves a full explanation here.

What is status epilepticus?
A seizure that lasts longer than 5 minutes, or having more than 1 seizure within a 5 minutes period, without returning to a normal level of consciousness between episodes is called status epilepticus. This is a medical emergency that may lead to permanent brain damage or death.

https://www.hopkinsmedicine.org/health/conditions-and-diseases/status-epilepticus

Pfizer reports 15 febrile seizures. These are considered a pediatric event, but Pfizer reported no children in this SOC. Were these seizures erroneously listed as febrile seizures or did Pfizer not report ages properly?

Another 29 events (5%) include disturbances of sensation or function including aura, narcolepsy, and "bad sensation." **Three meningitis cases** and **seven cases of encephalopathy** (disordered brain function often resulting in confusion or disturbance of mental clarity) were diagnosed.

Guillain-Barré syndrome, often described as immune attack on nerves with paralysis starting in the legs and ascending at times to the chest with inability to breathe, was diagnosed in **24** (4%). There were eight (1.5%) with **disturbances of walking**. Seventeen (3%) had **trigeminal neuralgia**, an extremely painful facial condition**. Multiple sclerosis** and other cases of damage to the sheath surrounding some nerve cells, typically found to be from an immune system attack, comprised **38** (7%) of the events. Seventeen (3%) cases of fibromyalgia were reported. Clinical diagnoses were specified only if there were two or more reports, so 20 diagnoses or syndromes were not given to us. What were they?

The neurologic adverse events above are **in addition to the strokes** reported in a separate report. This set of patients has suffered an equally serious group of lethal or potentially disabling disorders. We see double-digit fatalities in the first 90 days with a litany of dreaded new diagnoses among which are multiple sclerosis, seizures, Guillain-Barré, meningitis, and encephalopathy. **And half of the total events occurred within 24 hours of receiving the injection. In addition, at least 250 of the non-fatal events have no documented recovery.**

Pfizer's conclusion?

"This cumulative case review does not raise new safety issues. Surveillance will continue."

Post-Marketing Team's CONCLUSION
RECALL this unsafe "vaccine."

Post Marketing Team

https://dailyclout.io/wp-content/uploads/p2-Post-Marketing-Team-Neurologic-MicroReport.pdf (https://dailyclout.io/wp-content/uploads/p2-Post-Marketing-Team-Neurologic-MicroReport.pdf)

Spread the love
